Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $132 a share in cash for a total equity value of about $14.6 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback